Erratum (DOI:10.1016/j.bbmt.2008.10.030);A Phase II Trial of Autologous Stem Cell Transplantation Followed by Mini-Allogeneic Stem Cell Transplantation for the Treatment of Multiple Myeloma: An Analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 1, 2009, Pages 83-91

  Vesole, David H ^a   Zhang, Lijun ^b   Flomenberg, Neal ^c   Greipp, Philip R ^d   Lazarus, Hillard M ^e  

^a ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Allogeneic; Autologous; Multiple myeloma; Stem cell transplantation

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; METHYLPREDNISOLONE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER REGRESSION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HLA MATCHING; HUMAN; HUMAN CELL; MALE; MORTALITY; MULTIPLE MYELOMA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; SINGLE DRUG DOSE; STEM CELL MOBILIZATION;

EID: 58149199537     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.07.011     Document Type: Erratum

References (32)

1. Barlogie B., Kyle R.A., Anderson K.C., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24 (2006) 929-936
2. Bensinger W.I., Buckner C.D., Anasetti C., et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 88 (1996) 2787-2793
3. Crawley C., Iacobelli S., Bjorkstrand B., et al. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 109 (2007) 3588-3594
4. Gahrton G., Svensson H., Cavo M., et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 113 (2001) 209-216
5. Badros A., Barlogie B., Siegel E., et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 20 (2002) 1295-1303
6. Giralt S., Aleman A., Anagnostopoulos A., et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 30 (2002) 367-373
7. Lee C.K., Badros A., Barlogie B., et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol 31 (2003) 73-80
8. Crawley C., Lalancette M., Szydlo R., et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 105 (2005) 4532-4539
9. Maloney D.G., Molina A.J., Sahebi F., et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102 (2003) 3447-3454
10. Garban F., Attal M., Michallet M., et al. Prospective comparison of autologous stem cell transplantation followed by a dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107 (2006) 3474-3480
11. Kroger N., Schwerdtfeger R., Kiehl M., et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 100 (2002) 755-760
12. Bruno B., Rotta M., Patriarca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356 (2007) 1110-1120
13. Martino M., Console G., Irrera G., et al. High-dose therapy and autologous peripheral blood stem cell transplantation followed by a very low reduced-intensity regimen with fludarabine, cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients. Am J Hematol 81 (2006) 973-978
14. Georges G.E., Maris M.B., Maloney D.G., et al. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Biol Blood Marrow Transplant 13 (2007) 423-432
15. Rosinol L., Pérez-Simón J.A., Sureda A., et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 112 (2008) 3591-3593
16. Blade J., Samson D., Reece D., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102 (1998) 1115-1123
17. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
18. Cox D.R. Regression models and life-tables. J R Stat Soc B 34 (1972) 187-220
19. Tricot G., Vesole D.H., Jagannath S., et al. Graft-versus-myeloma effect: proof of principle. Blood 87 (1996) 1196-1198
20. Aschan J., Lonnqvist B., Ringden O., et al. Graft-versus-myeloma effect. Lancet 348 (1996) 346 346
21. Le Blanc R., Montminy-Métivier S., Bélanger R., et al. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplant 28 (2001) 841-848
22. Perez-Simon J.A., Martino R., Alegre A., et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol 121 (2003) 104-108
23. Peggs K.S., Thomson K., Hart D.P., et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 103 (2004) 1548-1556
24. Lacy M.Q., Gertz M.A., Dispenzieri A., et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 82 (2007) 1179-1184
25. Jagannath S., Durie B.G., Wolf J., et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129 (2005) 776-783
26. Richardson, Jagannath S., Raje N., et al. Lenalidomide, bortezomib, and dexamethasone (rev/vel/dex) as front-line therapy for patients with multiple myeloma (MM): preliminary results of a phase 1/2 study. Blood 110 (2007) abstract 187
27. Corradini P., Voena C., Tarella C., et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 17 (1999) 208-215
28. Kroger N. Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation. Leukemia 21 (2007) 1851-1858
29. Kroger N., Zabelina T., Ayuk F., et al. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol 34 (2006) 770-775
30. van de Donk N.W., Kroger N., Hegenbart U., et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 107 (2006) 3415-3416
31. Powles R., Sirohi B., Kulkami S., et al. Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an "operational cure"?. Bone Marrow Transplant 30 (2002) 479-484
32. Fassas A., Shaughnessy J., and Barlogie B. Cure of myeloma: hype or reality?. Bone Marrow Transplant 35 (2005) 215-224